Physician profile
Kiley L Davis
NPI 1184346116
$3,465.77
in general payments reported to CMS, 2019-2025
25 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $466 · 2024: $1,298 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.33 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $460.32 | 2023-2025 | |
| Abbvie INC. | $367.36 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $308.43 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $303.29 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $257.01 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $239.10 | 2023-2025 | Tremfya |
| Ucb, INC. | $225.78 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $189.24 | 2024-2025 | Nemluvio, Dysport |
| Sun Pharmaceutical Industries INC. | $169.39 | 2024-2025 | |
| Organon LLC | $150.57 | 2025 | Vtama, Hadlima |
| Arcutis Biotherapeutics, INC. | $135.27 | 2024-2025 | Zoryve |
| Amgen INC. | $133.33 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $107.97 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Blueprint Medicines Corporation | $107.21 | 2024-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $95.08 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $35.30 | 2024-2025 | Seysara |
| Revance Therapeutics, INC. | $25.22 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.08 | 2025 | Spevigo |
| Organogenesis INC. | $23.42 | 2025 | Puraply Wound Matrix |
| Mimedx Group, INC. | $22.40 | 2025 | |
| Lnhc, INC | $21.65 | 2025 | Zelsuvmi |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.34 | 2023 | Jublia |
| Journey Medical Corporation | $14.20 | 2025 | |
| Biowound Solutions, INC. | $13.18 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.